国家癌症研究所指定中心临床试验药学服务调查
该研究对美国61家NCI指定癌症中心进行横断面调查,评估26项临床试验药学服务的执行频率与重要性认知。结果显示19项服务被认为重要,但仅10项执行率超过50%;8项服务在重要性与执行率间存在至少40%的差距,最大差距见于研究者发起的试验开发、药物重整、治疗药物监测和口服化疗依从性评估。
要点
- 多数临床试验药学服务被认为重要,但实际执行率不足一半。
- 8项服务重要性与执行率差距超40%,涉及药物重整、TDM等。
- 提升药师在癌症试验中的参与需展示监管、安全与经济效益。
核心结论
- 癌症中心临床试验中,药师服务的重要性认知与实际执行之间存在显著差距。
研究设计与样本
- 横断面调查,覆盖61家NCI指定癌症中心,电子问卷收集数据,应答率59%(36/61)。
主要发现
- 26项服务中19项被认为重要,但仅10项执行频率超过50%。
- 8项服务重要性认知与执行率差距至少40%。
- 最大差距包括研究者发起的试验开发、药物重整、治疗药物监测和口服化疗依从性评估。
临床怎么用
- 临床药学智能体可参考此差距,在癌症临床试验中优先加强药物重整、TDM和口服化疗依从性评估等服务。
局限性
- 调查仅纳入NCI指定中心,应答率59%,结果可能不代表所有癌症中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pharmacy services provided in clinical trials at National Cancer Institute (NCI)-designated centers were assessed. METHODS: This was a cross-sectional survey of 61 NCI-designated cancer centers. Directors of pharmacy were contacted and data were collected electronically via Qualtrics over 2 months. Trial participants were asked to estimate the frequency that their sites performed 26 services and the perceived importance of these services. Services were examined with respect to the difference between their reported performance and their reported importance. Eight of the 26 services showed a difference of at least 40% between the proportion of respondents performing the activities "often" or "almost always" and the proportion considering them "important" or "very important." Demographic information was collected, as well as perceived barriers. RESULTS: Survey response rate was 59% (36 out of 61). The majority of services for clinical trials (19 out of 26) were viewed as important for pharmacists to perform; however, less than half (10 out of 26) were performed more than 50% of the time. Eight services had a gap of more than 40% when comparing the importance versus extent of implementation. Some of the largest gaps were reported in investigator-initiated trials development, medication reconciliation, therapeutic drug monitoring, and oral chemotherapy adherence assessment. Future studies can assist with cost justification by demonstrating the regulatory, safety, and financial benefits of pharmacist involvement in cancer trials. CONCLUSION: A survey of pharmacy directors at cancer centers revealed gaps between what respondents considered important pharmacist services in the provision of cancer clinical trials and the actual performance of those services in their institution.
引用
- Khandoobhai A, Poi M, Kelley K, et al. National survey of comprehensive pharmacy services provided in cancer clinical trials. Am J Health Syst Pharm. 2017. PMID: 28506975. doi:10.2146/ajhp160628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。